Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C. Evolving racial/ethnic disparities in AML survival in the novel therapy era , Blood Adv, 9: 2025,533-544
Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol: 2024
Takeshi Onoue, Andrew H Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M Smith, Shannon R McCurdy, Michael G Fradley, Joseph Carver, Jesse Chittams, Marielle Scherrer-Crosbie Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines , Cardio-Oncology, 10(1): 2024
Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander E Perl, David L Porter, Arlene Zeringue, Joseph H Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia , Haematologica, 8(109): 2024,2732-2737
Laczko D, Poveda-Rogers C, Matthews AH, Snaith O, Luger S, Bagg A, Caponetti GC, Morrissette JJD, Yang G. RAD21 mutations in acute myeloid leukemia , Leuk & Lymphoma: 2024
Matthews A, Fenu E, Skuli SJ, Harris JC, Lai C. Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach. , Leuk & Lymphoma: 2024
Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, Atallah E, Altman JK. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers , Am J Hematol, 99(4): 2024
Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia , Am J Hematol: 2023
Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard I, Carroll MP, Frey NV, Hexner E, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Jordan Bruno X, Hwang WT, Margolis D, Pratz KW. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. , Blood Adv
, 6(13): 2022,3997-4005
Matthews AH, Yui J, Chiang EY, Pishko AM, Cuker A, Cucchiara BL, George D, Sayani F, Mullen MT. Cerebral Infarction due to Severe ADAMTS-13 Deficiency with Normal Hematological Parameters: A Potential Cause of Cryptogenic Stroke. J Stroke Cerebrovasc Dis. , J Stroke Cerebrovasc Dis, 31(6): 2022,106431
